Weight-Loss drug semaglutide could be key to treating Obesity-Linked heart failure
NCT ID NCT05371496
First seen Mar 17, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This study looks at whether aggressive weight loss using semaglutide can improve symptoms in people with a specific type of heart failure linked to obesity. About 81 participants with a BMI of 30 or higher will receive either semaglutide or a placebo. The main goal is to measure changes in heart pressure during exercise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.